Home > Health A – Z > Esophagitis

Esophagitis

Inflammation of the esophagus (the tube that carries food from the mouth to the stomach).

PubMed Health Glossary
(Source: NIH - National Cancer Institute)

What works? Research summarized

Evidence reviews

Medical treatments for eosinophilic esophagitis (a chronic disease associated with increased numbers of eosinophils in the esophagus and symptoms of esophagitis)

Eosinophilic esophagitis (EE) is emerging globally as a significant cause of upper gastrointestinal disease in people with clinical symptoms of esophageal disease including a typical appearance of the esophagus and an increased number of eosinophil white blood cells when the esophagus is examined by an endoscope using high magnification.

Drug Class Review: Proton Pump Inhibitors: Final Report Update 5 [Internet]

Proton pump inhibitors decrease secretion of gastric acid. They act by blocking the last enzyme in the system that actively transports acid from gastric parietal cells into the gastrointestinal lumen, hydrogen–potassium adenosine triphosphatase, also known as the proton pump. Omeprazole, the first drug in this class, was introduced in 1989. Since then, 4 other proton pump inhibitors have been introduced: lansoprazole (1995), rabeprazole (1999), pantoprazole (2000), and esomeprazole (2001). In 2003 omeprazole became available over-the-counter in the United States. The purpose of this review is to compare the benefits and harms of different PPIs.

Infrequent chemoradiation-induced acute esophagitis in the Asian population: a meta-analysis of published clinical trials for unresectable stage III non-small cell lung cancer

Bibliographic details: Komiya T, Palla SL, Wang F, Perez RP, Huang CH.  Infrequent chemoradiation-induced acute esophagitis in the Asian population: a meta-analysis of published clinical trials for unresectable stage III non-small cell lung cancer. Thoracic Cancer 2014; 5(6): 565-569 Available from: http://onlinelibrary.wiley.com/doi/10.1111/1759-7714.12141/abstract

See all (107)

Summaries for consumers

Medical treatments for eosinophilic esophagitis (a chronic disease associated with increased numbers of eosinophils in the esophagus and symptoms of esophagitis)

Eosinophilic esophagitis (EE) is emerging globally as a significant cause of upper gastrointestinal disease in people with clinical symptoms of esophageal disease including a typical appearance of the esophagus and an increased number of eosinophil white blood cells when the esophagus is examined by an endoscope using high magnification.

Comparing Proton Pump Inhibitors

How do proton pump inhibitors compare in gastroesophageal reflux disease (GERD)?

Concurrent chemoradiotherapy reduces risk of death at two years compared to sequential chemoradiotherapy or radiotherapy alone in patients with stage III non small cell lung cancer

The use of chemotherapy concurrent with radiotherapy in locally advanced non‐small cell lung cancer may enhance the benefits of radiotherapy in terms of local and regional control and thus improve survival. A total of twenty‐five randomised studies (including 3752 patients) were included in this updated review: nineteen trials (2728 patients) comparing concurrent chemoradiotherapy with radiotherapy alone and six trials (1024 patients) comparing concurrent with sequential chemoradiotherapy. Both comparisons demonstrated significant reduction in risk of death with use of concurrent chemoradiation, with an associated increase in incidence of acute oesophagitis.

See all (13)

More about Esophagitis

Photo of an adult

Other terms to know:
Barrett's Esophagus, Esophagus, Inflammation

Keep up with systematic reviews on Esophagitis:

Create RSS

PubMed Health Blog...

read all...